All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Quizartinib recommended for approval in the EU
Bookmark this article
On September 15, 2023, quizartinib, an oral, highly potent and selective type II FLT3 inhibitor previously covered by the AML Hub, was recommended for approval in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of patients with newly diagnosed (ND) acute myeloid leukemia (AML) with FLT3-internal tandem duplication (FLT3-ITD) mutations in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib as a maintenance monotherapy.1 Quizartinib was also recently approved in the US and in Japan for the same indication.
This positive opinion is based on results from the phase III QuANTUM-First trial (NCT02668653), which were previously reported by the AML Hub.1 Quizartinib, in combination with standard chemotherapy, was associated with improved overall survival versus standard chemotherapy alone in patients with ND FLT3-ITD mutated AML.1
- Daiichi Sankyo. Quizartinib recommended for approval in EU by CHMP for patients with newly diagnosed FLT3-ITD positive AML. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202309/20230915_E2.pdf. Published Sept 15, 2023. Accessed Sept 18, 2023.
Your opinion matters
21 votes - 68 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox